Short Term CDK4/6 Inhibition Radiosensitizes Estrogen Receptor Positive Breast Cancers

PURPOSE: Cyclin-dependent kinase 4/6 (CDK4/6) inhibitors have improved progression free survival for metastatic, estrogen receptor positive (ER+) breast cancers, but their role in the non-metastatic setting remains unclear. We sought to understand the effects of CDK4/6 inhibition (CDK4/6i) and radia...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Clin Cancer Res
Main Authors: Pesch, Andrea M., Hirsh, Nicole H., Chandler, Benjamin C., Michmerhuizen, Anna R., Ritter, Cassandra L., Androsiglio, Marlie P., Wilder-Romans, Kari, Liu, Meilan, Gersch, Christina L., Larios, José M., Pierce, Lori J., Rae, James M., Speers, Corey W.
Formato: Artigo
Idioma:Inglês
Publicado em: 2020
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7744368/
https://ncbi.nlm.nih.gov/pubmed/32967938
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-20-2269
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados